Telli ML et al., 2007-08-10: Review of cardiac data from the adjuvant trastuzumab trials (NSABP B-31, N9831, HERA, BCIRG 006, FinHer) arguing that trastuzumab cardiotoxicity is not reliably reversible.
Results of follow-up cardiac evaluations of patients diagnosed with any degree of cardiotoxicity in the NSABP B-31 trial document that a clinically significant proportion of patients have sustained decrements in their LVEF to less than 50%.
Abstract (Results)
Telli ML et al., 2007-08-10: Review of cardiac data from the adjuvant trastuzumab trials (NSABP B-31, N9831, HERA, BCIRG 006, FinHer) arguing that trastuzumab cardiotoxicity is not reliably reversible. Comparator: the adjuvant trastuzumab arms vs their control arms within each trial. Maker Genentech/Roche; funder/COI not in the abstract. Same page: up to 4% had severe CHF during treatment and about 14% in NSABP B-31 discontinued trastuzumab for asymptomatic LVEF falls. This is the strongest primary counterweight to Seidman's 79%-improved figure, so both are recorded. Study type: review.
